Article Information
History
- April 1, 2024.
Article Versions
- Version 1 (January 24, 2024 - 20:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Rachael K. Ross1,*,
- Edward V. Nunes2,3,
- Mark Olfson1,2,3,
- Matisyahu Shulman2,3,
- Noa Krawczyk4,
- Elizabeth A. Stuart5 and
- Kara E. Rudolph1
- 1Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
- 2Department of Psychiatry, Columbia University Irving Medical Center
- 3New York State Psychiatric Institute, New York, NY
- 4Department of Population Health, New York University, New York, NY
- 5Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
- ↵*Corresponding author: Dr. Rachael Ross, Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY 10032; rachael.k.ross{at}columbia.edu
Posted April 01, 2024.
WITHDRAWN: Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
